COVID-19 antibody ‘cocktail’ protects chronically ill: study
Distress signal from fat cells prompts heart to shore up defenses against consequences of obesity
20 August 2021Demand for COVID antibody drugs soars in hard-hit states
20 August 2021COVID-19 antibody ‘cocktail’ protects chronically ill: study
A monoclonal antibody cocktail against the COVID-19 virus discovered at Vanderbilt University Medical Center and developed by AstraZeneca reduced the risk of symptoms in a study of immunocompromised and chronically ill adults later exposed to the virus by 77%, the company announced today.
